Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Electrotherapeutic Management of Patients with Heart Failure

  • 27 Accesses

  • 1 Citations

Abstract

Heart failure is associated with poor long term survival due to progressive refractory heart dysfunction and sudden cardiac death. Cardiac resynchronization through atrio-biventricular pacing has been introduced to treat patients affected by drug-refractory heart failure with desynchronized ventricular activation, as for complete left bundle branch block. The technique is aimed to overcome interventricular and intraventricular conduction delays leading to ventricular dysynchrony, paradoxical septal wall motion, presystolic mitral regurgitation and reduced diastolic filling times. Short term studies demonstrated that biventricular pacing (and perhaps left ventricular pacing alone) may improve both systolic and diastolic function. Initial studies in patients receiving long term pacing consistently showed significant QRS shortening associated with improvement in symptoms, left ventricular ejection fraction, exercise tolerance, quality of life and New York Heart Association functional class. As far as sudden cardiac death prevention in heart failure is concerned, implantable cardioverter defibrillator (ICD) implantation has been demonstrated to be the most effective therapy in patients with prior cardiac arrest due to ventricular fibrillation or poorly tolerated ventricular tachycardia. Low left ventricular ejection fraction, unsustained ventricular tachycardia and inducibility at electrophysiological study also may identify high risk patients requiring ICD implantation. Further studies are needed to evaluate the effect of cardiac resynchronization on hard end-points, such as survival and long term clinical outcome, and to upgrade risk stratification criteria to be used in selection of candidates for ICD implantation.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Grave, EJ. Detailed diagnoses and procedures. National Hospital Discharge Survey, 1989. In: National Center of Health Statistics, editors. Vital and Health Statistics 1991. Series 13, No. 107. Washington, DC: US Government Printing Office, 1991. DHHS publication no. (PHS) 91–1768

  2. 2.

    Ho Kkl, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure. The Framingham Study. J Am Coll Cardiol 1993; 22 Suppl. A: 6A–13A

  3. 3.

    MERIT HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XR Randomized Intervention Trial in Congestive Heart Failure (MERIT HF). Lancet 1999; 353: 2001–7

  4. 4.

    O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a new approach. J Heart Lung Transplant 1994; 13: S107–12

  5. 5.

    Hart SM. Influence of beta blockers on mortality in chronic heart failure. Ann Pharmacother 2000; 34(12): 1440–51

  6. 6.

    Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354(9172): 9–12

  7. 7.

    Baruch L, Anand I, Cohen IS, et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999; 99(20): 2658–64

  8. 8.

    Hochleitner M, Zechmann W, Hortnagl H, et al. Usefulness of physiologic dual chamber pacing in drug-resistant idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 66: 198–202

  9. 9.

    Hochleitner M, Hortnagl H, Fridrich L, et al. Long-term efficacy of physiologic dual chamber pacing in the treatment of end stage idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 70: 1320–5

  10. 10.

    Brecker SJD, Xiao HB, Sparrow J, et al. Effects of dual chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet 1992; 340: 1308–12

  11. 11.

    Auricchio A, Sommariva L, Salo RW, et al. Improvement of cardiac function in patients with severe congestive heart failure and coronary artery disease by dual chamber pacing with shortened AV delay. PACE 1993; 16: 2034–43

  12. 12.

    Innes D, Leitch JW, Fletcher PJ. VDD pacing at short atrioventricular intervals does not improve cardiac output in patients with dilated heart failure. PACE 1994; 17: 959–65

  13. 13.

    Linde C, Gadler F, Edner M, et al. Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure. Am J Cardiol 1995; 75: 919–23

  14. 14.

    Gold MR, Feliciano Z, Gottlieb SS, et al. Dual-chamber pacing with short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol 1995; 26: 957–73

  15. 15.

    Brecker SJD, Gibson GD. What is the role of pacing in dilated cardiomyopathy?. Eur Heart J 1996; 17: 819–24

  16. 16.

    Harper GR, Pina IL, Kutalek SP. Intrinsic conduction maximizes cardiopulmonary performance in patients with dual chamber pacemakers. PACE 1991; 14: 1787–91

  17. 17.

    Giudici MC, Thomburg GA, Buck DL, et al. Comparison of right ventricular outflow tract and apical lead permanent pacing on cardiac output. Am J Cardiol 1997; 79: 209–12

  18. 18.

    Buckingham TA, Candinas R, Schlapfer J, et al. Acute hemodynamic effects of atrioventricular pacing at different sites in the right ventricle individually and simultaneously. PACE 1997; 20 (Part I): 909–15

  19. 19.

    Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. PACE 1994; 17: 1974–9

  20. 20.

    Cazeau S, Ritter P, Lazarus A, et al. Multisite pacing for end-stage heart failure. Early experience. PACE 1996; 19: 1748–57

  21. 21.

    Aaronson K, Schwartz J, Chen T-M, et al. Development and prospective evaluation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660–7

  22. 22.

    Xiao H, Ror C, Fujimoto S, et al. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996; 53: 163–70

  23. 23.

    Schoeller R, Andresen D, Buttner P, et al. First or second degree atrioventricular block as a risk factor in idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71: 720–6

  24. 24.

    Grines C, Bashore T, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block: the effect of interventricular asynchrony. Circulation 1989; 79: 845–53

  25. 25.

    Xiao H, Brecker S, Gibson D. Effects of abnormal activation on the time course of left ventricular pressure pulse in dilated cardiomyopathy. Br Heart J 1992; 68: 403–7

  26. 26.

    Xio Lee C, Gibson D. Effects of left bundle branch block on diastolic function in dilated cardiomyopathy. Br Heart J 1991; 66: 443–7

  27. 27.

    Ansalone G, Trambaiolo P, Giorda GP, et al. Multisite stimulation in refractory heart failure. G Ital Cardiol 1999; 29: 451–9

  28. 28.

    Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999; 99: 2993–3001

  29. 29.

    Etienne Y, Mansourati J, Gilard M, et al. Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial fibrillation. Am J Cardiol 1999; 83: 1138–40

  30. 30.

    Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol 1998; 32(7): 1825–31

  31. 31.

    Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different ventricular pacing sites in patients with severe heart failure. Results of an acute hemodynamic study. Circulation 1997; 96: 3273–7

  32. 32.

    Foster AH, Gold MR, McLauglin JS. Acute hemodynamic effects of atrio-biventricular pacing in humans. Ann Thorac Surg 1995; 59: 294–300

  33. 33.

    Kass D, Chen-Huan C, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999; 99: 1567–73

  34. 34.

    Hamdan MH, Zagrodzky JD, Joglar JA, et al. Biventricular pacing decreases sympathetic activity compared with right ventricular pacing in patients with depressed ejection fraction. Circulation 2000; 102: 1027–32

  35. 35.

    Auricchio A, Salo R. Acute hemodynamic improvement by pacing in patients with severe congestive heart failure. PACE 1997; 20(I): 313–24

  36. 36.

    Saxon LA, Kerwin WF, Cahalan MK, et al. Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function. J Cardiovasc Electrophysiol 1998; 9(1): 13–21

  37. 37.

    Daubert JC, Ritter P, Le Breton H, et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. PACE 1998; 21: 239–45

  38. 38.

    Auricchio A, Klein H, Tockman B, et al. Transvenous biventricular pacing for heart failure: can the obstacles be overcome?. Am J Cardiol 1999; 83: 136D–42D

  39. 39.

    Lurie K, Benditt D, Samiah N, et al. A transvenous ‘long guiding sheath’ technique for permanent left ventricular pacing lead implantation in patients with heart failure [abstract 4414]. Circulation 1998; 98(17): I–841

  40. 40.

    Curnis A, Neri R, Mascioli G, et al. Left ventricular pacing lead choice based on coronary sinus venous anatomy. Eur Heart J 2000; 2 Suppl. J: J31–5

  41. 41.

    Ricci R, Ansalone G, Toscano S, et al. Cardiac resynchronization: materials, technique and results. The InSync Italian Registry. Eur Heart J 2000; 2 Suppl. J: J6–15

  42. 42.

    Gras D, Mabo P, Tang T, et al. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. PACE 1998; 21: 2249–55

  43. 43.

    Gras D, Ritter P, Lazarus A, et al. Long-term outcome of advanced heart failure patients with cardiac resynchronization therapy [abstract]. PACE 2000; 23: 658

  44. 44.

    Bakker P, Chin K, Sen A, et al. Biventricular pacing improves functional capacity in patients with end-stage congestive heart failure. Early experience. PACE 1995; 19(II): 1748–57

  45. 45.

    Braunschweig F, Linde C, Gadler F, et al. Reduction of hospital days by biventricular pacing. J Heart Fail. In press

  46. 46.

    Zardini M, Tritto M, Bargiggia G, et al. The InSync Italian Registry: analysis of clinical outcome and considerations on the selection of candidates to left ventricular resynchronization. Eur Heart J 2000; 2 Suppl. J: J16–22

  47. 47.

    Porciani MC, Puglisi A, Colella A, et al. Echocardiographic evaluation of the effect of biventricular pacing: the InSync Italian Registry. Eur Heart J 2000; 2 Suppl. J: J23–30

  48. 48.

    Alonso C, Leclercq C, Victor F, et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. Am J Cardiol 1999; 84: 1417–21

  49. 49.

    Auricchio A, Stellbrink C, Sack S, et al. The pacing therapies for congestive heart failure (PATH-CHF) Study: rationale, design and end-points of a prospective, randomized, multicenter study. Am J Cardiol 1999; 83: 130D–5D

  50. 50.

    Auricchio A, Stellbrink C, Sack S, et al. Chronic benefit as a result of pacing in congestive heart failure. Results of the PATH-CHF trial [abstract]. J Card Fail 1999; 5(3): I–78

  51. 51.

    Cazeau S, Leclerq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873–80

  52. 52.

    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576–83

  53. 53.

    Kuck KH, Cappato R, Siebeis J, et al., for the CASH Investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–54

  54. 54.

    Connolly SJ, Gent M, Roberts RS, et al. for the CIDS Investigators. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–302

  55. 55.

    Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998; 31: 1175–209

  56. 56.

    Domanski MJ, Saksena S, Epstein AE, et al., for the AVID Investigators. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 1999; 34: 1090–5

  57. 57.

    Moss AJ, Hall WJ, Cannoni DS, et al., for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with prior myocardial infarction, low ejection fraction and asymptomatic non-sustained ventricular tachycardia. N Engl J Med 1996; 335(26): 1933–40

  58. 58.

    Buxton AE, Lee LL, Fisher JD, et al., for the Multicenter Unsustained Tachycardia Trial (MUSTT) Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–90

  59. 59.

    Moss AJ. Implantable cardioverter defibrillator therapy. The sickest patients benefit the most. Circulation 2000; 101: 1638–40

  60. 60.

    Saxon L, Boehmer J, Hummel J, et al., for the VIGOR CHF and VENTAR CHF Investigators. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. Am J Cardiol 1999; 83: 120D–3D

  61. 61.

    Bristow M, Feldman A, Saxon L. Heart failure management using implantable devices for ventricular resynchronization: comparison of medical therapy, pacing and defibrillation in chronic heart failure (COMPANION) trial. J Card Fail 2000; 6(3): 276–85

  62. 62.

    Cleland JF, Tavazzi L, Klein W, et al. Initial therapy assessment and current European outcome trials of cardiac resynchronization therapy for heart failure. Patients with left ventricular desynchronization [abstract]. Europace 2000; I Suppl. D: 116

Download references

Author information

Correspondence to Prof Massimo Santini.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Santini, M., Ricci, R., Pignalberi, C. et al. Electrotherapeutic Management of Patients with Heart Failure. Am J Cordiovosc Drugs 1, 227–231 (2001). https://doi.org/10.2165/00129784-200101040-00001

Download citation

Keywords

  • Left Ventricular Ejection Fraction
  • Implantable Cardioverter Defibrillator
  • Biventricular Pace
  • Left Ventricular Lead
  • Implantable Cardioverter Defibrillator Implantation